Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching
Color Changes During Tooth Formation
About this trial
This is an interventional prevention trial for Color Changes During Tooth Formation focused on measuring bleaching agent, tooth bleaching, sensibility
Eligibility Criteria
Inclusion Criteria:
- will be included patients 18 years old and over
- with good general and oral health
- with the eight upper front teeth free of cavities and restorations in the buccal cavity
The initial color of those teeth must be C2 or dark, comparing with scale Vita Lumin (Vita Zahnfabrik, Bad Säckingen, Germany) organized in order of value.
Exclusion Criteria:
- shall be excluded patients who underwent any previous form of bleaching procedure
- lactating and pregnant patients
- who relates sensitivity
- severe dental browning (tetracycline staining, fluorosis or endodontics)
- with parafunctional habit or any other type of oral disease
Still will be excluded patients who have systemic conditions as stomach problems, heart, kidney and liver, or using any continuous drug with anti-inflammatory and antioxidant action.
Sites / Locations
- Universidade Estadual de Ponta Grossa
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Experimental
placebo group
The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.